Literature DB >> 8032650

Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.

S J McAuliffe1, J A Moors, H B Jones.   

Abstract

1. This study compares a cyclo-oxygenase inhibitor (aspirin), a 5-HT2 antagonist (ZM170809) and a combined thromboxane synthase inhibitor/receptor antagonist (ZD1542) as adjuncts to tissue plasminogen activator (rt-PA). 2. Application of an anodal current (332 +/- 4.1 microA) to the stenosed left circumflex coronary artery of 20 anaesthetized dogs produced a stable platelet-rich occlusive thrombus. 3. After initial i.v. administration of recombinant human tissue type plasminogen activator (rt-PA, 3 mg bolus +2 mg kg-1 h-1 for 30 min) thrombolysis occurred in 15 out of 20 dogs. All 15 dogs reoccluded. 4. The second i.v. administration of rt-PA in the presence of either aspirin, ZM170809, ZD1542 or saline resulted in thrombolysis in all 20 dogs. 5. Both the combined thromboxane synthase inhibitor/receptor antagonist (ZD1542) and 5-HT2 antagonist (ZM170809) significantly (P < 0.05) reduced the time taken to lyse the thrombus compared with the saline group. The times were 14.4 +/- 2.7 min, 18.0 +/- 3.9 min and 36.8 +/- 6.2 min for ZD1542, ZM170809 and saline respectively. 6. Aspirin did not offer any additional benefit to using rt-PA alone. The times to thrombolysis were 36.8 +/- 8.4 min for aspirin and 36.8 +/- 6.2 min for the saline group. 7. The number of dogs in which the circumflex coronary artery reoccluded within 60 min of terminating the second infusion of rt-PA were five for saline, four for aspirin, two for ZD1542 and two for ZM170809. 8. These results indicate that both ZD1542 and ZM170809 are more effective adjuncts than aspirin in thrombolysis and may provide an improvement in current clinical practice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032650      PMCID: PMC1910308          DOI: 10.1111/j.1476-5381.1994.tb13063.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.

Authors:  C L Lucore; B E Sobel
Journal:  Circulation       Date:  1988-03       Impact factor: 29.690

2.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.

Authors:  H K Gold; R C Leinbach; H D Garabedian; T Yasuda; J A Johns; E B Grossbard; I Palacios; D Collen
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

3.  Interaction between the effects of 5-hydroxytryptamine and adrenaline on the growth of platelet thrombi in the coronary artery of the anaesthetized dog.

Authors:  S J McAuliffe; H M Snow; B Cox; C C Smith; M I Noble
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

4.  Evidence for functional 5-HT2 receptor sites on human blood platelets.

Authors:  F De Clerck; B Xhonneux; J Leysen; P A Janssen
Journal:  Biochem Pharmacol       Date:  1984-09-01       Impact factor: 5.858

5.  Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents.

Authors:  J L Romson; D W Haack; B R Lucchesi
Journal:  Thromb Res       Date:  1980-03-15       Impact factor: 3.944

6.  Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.

Authors:  P R Eisenberg; L A Sherman; A S Jaffe
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

7.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.

Authors:  E Falk
Journal:  Circulation       Date:  1985-04       Impact factor: 29.690

8.  Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.

Authors:  R J Shebuski; B L Storer; T Fujita
Journal:  Thromb Res       Date:  1988-12-01       Impact factor: 3.944

9.  Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.

Authors:  P Golino; J H Ashton; J McNatt; P Glas-Greenwalt; S K Yao; R A O'Brien; L M Buja; J T Willerson
Journal:  Circulation       Date:  1989-04       Impact factor: 29.690

10.  Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.

Authors:  P Golino; J H Ashton; P Glas-Greenwalt; J McNatt; L M Buja; J T Willerson
Journal:  Circulation       Date:  1988-03       Impact factor: 29.690

View more
  1 in total

1.  2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.

Authors:  Claire R Sharp; Marie-Claude Blais; Corrin J Boyd; Benjamin M Brainard; Daniel L Chan; Armelle de Laforcade; Robert Goggs; Julien Guillaumin; Alex Lynch; Erin Mays; Duana McBride; Tommaso Rosati; Elizabeth A Rozanski
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.